Clinical Trial

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, Phase I clinical study with expansion. It will assess the safety and efficacy of high-dose ascorbate administered concomitantly with azacitidine and venetoclax in newly diagnosed AML.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-10
Trial Details
NCT Number NCT07177079
Lead Sponsor Kittika Poonsombudlert
Conditions Acute Myeloid Leukemia
Enrollment 30 participants
Start Date 2026-03-18
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-09